PIK3CA and breast carcinoma: In addition, we assessed the effects of PI3K and Cyclin-Dependent-Kinase-4/6 (CDK4/6) inhibitor combinations on the HPV+/HPV− CU-OP lines and revealed positive synergistic effects similar to that for certain breast cancer types [17,46].